Evidence map›Paper›PMID 40741203›Full record

ReviewWorld journal of clinical oncology2025

Edge learning applications in the prediction and classification of combined hepatocellular-cholangiocarcinoma: A comprehensive narrative review.

Sami Akbulut, Cemil Colak

Abstract readReview
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sami AkbulutDepartment of Surgery and Liver Transplantation, Inonu University Faculty of Medicine, Malatya 44280, Türkiye.
Cemil ColakBiostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya 44280, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare heterogeneous primary malignant liver tumor containing both hepatocellular and cholangiocarcinoma features. The complex presentation of cHCC-CCA tends to be poorly investigated, and the information derived from traditional diagnostic techniques (histopathology and radiological imaging) is often not optimal. Since cHCC-CCA is usually difficult to diagnose due to complex histopathological features (edge learning) as excessive photos, hence, achieves treatment delays and poor prognosis, the incorporation of advanced artificial intelligence like edge learning is able to improve the patient's outcome. Using artificial intelligence, particularly deep learning, has recently opened new doorways for the improvement of diagnostic accuracy. If artificial intelligence models are deployed on local devices, edge learning exercises this type of learning, which provides real time processing, improved data privacy and reduced bandwidth usage. This narrative review investigates the conceptual formulation of edge learning together with its opportunities for clinical applications in the prediction and classification of cHCC-CCA, the technical solution strategies, the clinical benefits it offers, and associated challenges and future directions.

Indexed as

Artificial intelligenceCombined hepatocellular-cholangiocarcinomaDiagnostic accuracyDisease predictionEdge learning

Identifiers

PMID40741203
PMCPMC12305016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.